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Research, University of Maryland School of Pharmacy, Baltimore, MD, USAA B S T R A C TAn outcome assessment, the patient assessment used in an endpoint, is
the measuring instrument that provides a rating or score (categorical or
continuous) that is intended to represent some aspect of the patient’s
health status. Outcome assessments are used to deﬁne efﬁcacy end-
points when developing a therapy for a disease or condition. Most
efﬁcacy endpoints are based on speciﬁed clinical assessments of
patients. When clinical assessments are used as clinical trial outcomes,
they are called clinical outcome assessments (COAs). COAs include any
assessment that may be inﬂuenced by human choices, judgment, or
motivation. COAs must be well-deﬁned and possess adequate measure-
ment properties to demonstrate (directly or indirectly) the beneﬁts of a
treatment. In contrast, a biomarker assessment is one that is subject to
little, if any, patient motivational or rater judgmental inﬂuence. This is
the ﬁrst of two reports by the ISPOR Clinical Outcomes Assessment –
Emerging Good Practices for Outcomes Research Task Force. This report
provides foundational deﬁnitions important for an understanding of
COA measurement principles. The foundation provided in this report
includes what it means to demonstrate a beneﬁcial effect, how assess-
ments of patients relate to the objective of showing a treatment’s
beneﬁt, and how these assessments are used in clinical trial endpoints.
In addition, this report describes intrinsic attributes of patient assess-
ments and clinical trial factors that can affect the properties of the
measurements. These factors should be considered when developing or
reﬁning assessments. These considerations will aid investigators design-
ing trials in their choice of using an existing assessment or developing a
new outcome assessment. Although the focus of this report is on the
development of a new COA to deﬁne endpoints in a clinical trial, theseee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.08.006
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ndence to: Marc K. Walton, 125 Crystal Spring Drivprinciples may be applied more generally. A critical element in apprais-
ing or developing a COA is to describe the treatment’s intended beneﬁt
as an effect on a clearly identiﬁed aspect of how a patient feels or
functions. This aspect must have importance to the patient and be part
of the patient’s typical life. This meaningful health aspect can be
measured directly or measured indirectly when it is impractical to
evaluate it directly or when it is difﬁcult to measure. For indirect
measurement, a concept of interest (COI) can be identiﬁed. The COI
must be related to how a patient feels or functions. Procedures are then
developed to measure the COI. The relationship of these measurements
with how a patient feels or functions in the intended setting and
manner of use of the COA (the context of use) could then be deﬁned.
A COA has identiﬁable attributes or characteristics that affect the
measurement properties of the COA when used in endpoints. One of
these features is whether judgment can inﬂuence the measurement,
and if so, whose judgment. This attribute deﬁnes four categories of
COAs: patient reported outcomes, clinician reported outcomes, observer
reported outcomes, and performance outcomes. A full description as
well as explanation of other important COA features is included in this
report. The information in this report should aid in the development,
reﬁnement, and standardization of COAs, and, ultimately, improve their
measurement properties.
Keywords: clinical outcome assessment, concept of interest, context of
use, treatment beneﬁt.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Establishing the value of medical interventions from the perspec-
tive of multiple parties—patients, health care providers, regulators,and payers—is essential to the availability and adoption of thera-
pies. An important element of the information establishing a
therapy’s value is the evidence provided from clinical trials evalu-
ating the intervention’s effect. (The term “therapy” is usedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
e, Ashton, MD 20861.
Background to the Task Force
Since 2009, ISPOR has published eight patient reported outcome
(PRO) task force reports based on addressing aspects of the
development and application of PROs. These reports are
consistent with the US Food and Drug Administration’s (FDA’s)
guidance for industry, “Patient Reported Outcome Measures:
Use in Medical Product Development to Support Labeling
Claims,” that described how the FDA would evaluate the
adequacy and appropriateness of PRO measures used as
effectiveness endpoints in clinical trials.
With the FDA’s evolution toward the review and qualifica-
tion of clinical outcome assessments (COAs), defined as any
reported assessment used to support primary or secondary
endpoints to document treatment benefit, former PRO task
force members submitted a proposal to focus on a specific type
of COA—clinician reported outcomes (ClinROs).
In January 2013, the ISPOR Health Science Policy Council
recommended the formation of a ClinRO Good Practices for
Outcomes Research Task Force. The Board of Directors subse-
quently approved the task force.
Members and primary reviewers were selected to represent
a diverse range of perspectives, including government (US
FDA), academia, research organizations, and the pharmaceu-
tical industry. The task force leadership group comprised
experts in PRO and other assessment and development,
psychometrics, clinical trial data collection, and regulatory
affairs. In addition, the task force had international represen-
tation with members from the European Medicines Agency
and reviewers.
The task force met approximately every 5 weeks by tele-
conference to develop an outline and discuss issues to be
included in the report. In addition, task force members met in
person at ISPOR international meetings. All task force members,
as well as primary reviewers, reviewedmany drafts of the report
and provided frequent feedback in both oral and written
comments.
In the course of task force deliberations, in response to
specific comments and suggestions from reviewers, and a
growing concern about length, it became apparent that the
material would need to be covered in two task force reports to
be thorough, covering the essential points, yet keep the report
readable and digestible. With permission from the editors of
Value in Health, the material has been split into two articles. This
article lays the groundwork explaining the important concepts
and definitions that underpin COAs. The second article delves
into the specific aspects of ClinRO assessments and makes good
measurement practices recommendations.
Preliminary findings and recommendations were presented
four times in forum and workshop presentations at the ISPOR
annual European congresses and international meetings in the
period 2013 to 2015. Comments received during these presenta-
tions were addressed in subsequent drafts of the report. In
addition, the draft task force report was sent out to the nearly
500-person ISPOR PRO Review Group twice.
All comments were considered, and most were substantive
and constructive. The comments were discussed by the task
force in a series of teleconferences and addressed as appro-
priate in revised drafts of the report. All written comments are
published at the ISPOR Web site on the task force’s Web page:
http://www.ispor.org/taskForces/Clinical-Outcomes-Assess
ment.asp.
The task force report and Web page may also be accessed
from the ISPOR homepage (www.ispor.org) via the purple
Research Tools menu, ISPOR Good Practices for Outcomes
Research, heading: Patient Reported & Clinician Reported Out-
comes Methods and link: http://www.ispor.org/workpaper/prac
tices_index.asp. A list of leadership group members is also
available via the task force’s Web page.
Once consensus was reached by all task force members, the
final report was submitted to Value in Health in August 2015.
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the person, irrespective of whether the intervention is intended to
improve, or prevent additional, adverse effects in patients of a
disease already established, or prevent onset of a disorder not yet
affecting a person.) Measurement of the beneﬁcial effect relies on a
speciﬁed assessment of study patients—evaluating how they feel,
function, or survive. This evaluation is used in deﬁning the trial’s
endpoint and in comparing patient groups within the study.
For many diseases, there is no agreed-upon, well-deﬁned, and
reliable method for evaluating a particular disease manifestation
of interest, and in some diseases not for any important manifes-
tation [1–11]. In other diseases, current outcome evaluation
methods have known weaknesses, such as poor reliability,
limited ability to detect change, inadequate interpretability of
changes [12–15], or uncertain validity [16–18]. In some clinical
ﬁelds, published clinical trials have used multiple outcome
evaluation methods without an adequate understanding of the
characteristics of any of the used methods [19,20].
This lack of understanding of outcome assessment attributes
and how these affect measurement plus the dearth of good tools
for outcome measurement of disease manifestations inhibits
therapy development. New, improved, and better-understood
methods of assessing the patient can move therapy development
forward. Consequently, many investigators are seeking
to develop new instruments for outcome measurement or to
evaluate the quality of existing instruments. Unfortunately,
developing and evaluating new instruments for clinical trial
patient assessment or improving existing assessments can be
difﬁcult. It is hoped that the information in this report will serve
as a basis of understanding, ultimately leading to improvedexisting instruments and development of new instruments with
solid measurement capabilities.
This is the ﬁrst of two reports by the ISPOR Clinical Out-
comes Assessment – Emerging Good Practices Task Force.
In this report, we delve into the attributes or characteristics
that affect the measurement properties of the assessment
when used in endpoints. We provide a clear understanding of
what beneﬁcial effect means, how assessments of patients
relate to demonstration of a treatment’s beneﬁt, and how
these assessments are used in study endpoints. In addition,
this report describes intrinsic attributes of assessments and
clinical trial factors that can affect the measurement properties
that should be considered when developing or reﬁning patient
assessments.
These concepts are integral to the development of patient
assessment tools of any type for clinical trials. The terminology,
types, and distinguishing characteristics deﬁned and discussed in
this report provide a foundation upon which new outcome
assessments can be developed and shown to be well deﬁned
and reliable. The explanations and recommendations in this
report will also aid investigators considering inclusion of new
outcome assessments in the design of clinical trials.
The second report from this task force, “Developing and
Evaluating Clinician Reported Outcome (ClinRO) Assessments of
Treatment Beneﬁt – Emerging Good Measurement Practices” (J.H.
Powers, D.L. Patrick, M.K. Walton, et al., unpublished report),
describes principles for the development of new and evaluation
of existing ClinRO assessments. Some of the concepts described
in these two reports have been discussed in other publications
[21–23], and in guidance from the US Food and Drug
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this report will further contribute to improving the development
of good clinical assessments for use in study endpoints. Recom-
mendations to guide the process of developing outcome assess-
ments with good measurement properties, however, are beyond
the scope of this report.Treatment Beneﬁt
The primary goal of clinical efﬁcacy trials is to provide evidence
that a treatment is effective. A conclusion that a therapy is
effective means that there is a treatment beneﬁt presumably
caused by the therapy’s use.
A treatment beneﬁt is a favorable effect on a meaningful
aspect of how a patient feels or functions in his or her life or on
his or her survival. Two phrases in this deﬁnition deserve
emphasis to ensure clarity. One is meaningful aspect—the effect
on how a patient feels or functions should be meaningful to the
patient. If the effect is not meaningful to the patient, it is not a
beneﬁt to the patient. More speciﬁcally, this means the treatment
effect has a positive impact on an aspect of health affected by the
disease that is an alteration in the patient’s feeling or function-
ing. It is an aspect of health that the patient cares about and
has a preference that this aspect 1) does not become worse, 2)
improves, or 3) is prevented.
The second part of the deﬁnition is in their life. This means the
treatment beneﬁt affects an aspect that occurs in the patient’s
usual (typical) life. A treatment effect is not a treatment beneﬁt if
it is solely an alteration in performing a speciﬁc task that occurs
only in the medical clinic and has no deﬁned relationship with
any usual activity the patient does (or would want to do) in life
outside of the clinical trial setting. Establishing a well-understood
relationship of the measurement with the patient’s usual life is
central to the conclusion that the observed effect is actually a
treatment beneﬁt.
However, if a purely clinic-based procedure provides a meas-
urement of a simpliﬁed patient activity that has an adequately
understood relationship with the patient’s function in life, then a
treatment’s effect on that measurement can be interpreted as a
treatment beneﬁt. For example, speciﬁc differences in clinic-
based pulmonary function tests in patients with asthma have
been empirically shown to have a relationship with meaningful
effects for similar patients in their usual life.
Patients suffering from the same disease may exhibit different
symptoms or manifestations. Some manifestations, which are
the most important ones to those patients exhibiting them, are
not well suited to controlled clinical trial demonstration of
treatment beneﬁt in a broader patient population. Moreover,
differences in a patient’s life circumstances, unrelated to the
disease, may inﬂuence which of these symptoms are deemed the
“most important” to an individual patient.
Furthermore, a therapy typically has a varying level of effect
on different disease manifestations. This means that efﬁcacy
could be readily shown on only some manifestations. These
symptoms may or may not be the most important to patients.
Consequently, the speciﬁc disease aspect selected for clinical
trial evaluation may not be the most important for each patient
in a study. In many trials, several disease aspects of varying
importance to patients are evaluated to provide a more compre-
hensive understanding of a treatment’s beneﬁts, for example,
secondary endpoints in a clinical trial. Nonetheless, the eval-
uated aspects of how a patient feels or functions must have
some meaning (i.e., some amount of importance) to patients who
have the disease.
Controlled clinical trials, for example, phase 3 trials, are
designed to show a difference in the study endpoint results forpatients who received the investigational treatment as compared
with those who received a comparator treatment (often a pla-
cebo). These rigorous studies are the usual source of evidence to
support a conclusion of treatment beneﬁt. Therefore, the study
endpoint difference between treatment and control patients
needs to show or be conﬁdently interpreted as indicating a
meaningful effect on how patients feel, function, or survive.
The importance of the treatment beneﬁt provided by a therapy
is related to both the type of beneﬁt (a feature of the assessment)
and the amount of that beneﬁt that occurs (the size of the
treatment effect, such as the magnitude of difference on a
continuous scale or the percentage difference of patients achiev-
ing a particular outcome state).
In contrast, there are many measurements that are consid-
ered related to feeling or functioning for which the meaning
(importance) to patients in their typical life is not self-evident
and has not been adequately evaluated, for example, many
cognitive function tests and in-clinic exercise tests. In diseases
in which improving one or more speciﬁc aspects of feeling or
functioning is the intended beneﬁt, an inability to interpret a
measurement as meaningful leads to an inability to demonstrate
the therapy’s treatment beneﬁt. Methods for evaluation that
describe or can be used to infer meaningful aspects of how
patients feel or function are necessary for the evaluation of these
disease treatments. This discussion often uses patient function
to describe features of assessments or as examples. The impor-
tant points and attributes, however, are applicable to assess-
ments of both feelings and function.
This report focuses on assessments of how patients feel or
function, not survival. Survival as an outcome assessment (often
duration of survival) is distinctly different from feelings or
functions, which can be regarded as quality of survival in
contrast to duration of survival. Unlike many types of feeling or
functioning, mortality has well-deﬁned means for determination
(when not restricted to cause-attributed mortality) with readily
understood meaning. The meaning of death remains clear even
in diseases in which some people might view certain nonfatal
outcomes of the disease, for example, severe irreversible disabil-
ity, as also highly undesirable. (See J.H. Powers, D.L. Patrick, M.K.
Walton, et al., unpublished report, for further discussion of
mortality.)The Relationship between Patient Assessments and
Study Endpoints
The primary objective of phase 3 studies is to demonstrate a
treatment-related difference in patient outcomes through an
analysis of patient assessment study data as speciﬁed by the
endpoint description. An outcome assessment, the patient assess-
ment used in an endpoint, is the measuring instrument that
provides a rating or score (categorical or continuous) that is
intended to represent some aspect of the patient’s health status.
Most, but not all, phase 3 clinical trials use some type of clinical
assessment as the basis for the primary endpoint. The measure-
ment properties of the outcome assessment include content
validity, reliability, ability to detect change, and interpretability—
the ability to interpret or understand the relationship between the
study results and the treatment beneﬁt. These characteristics will
strongly inﬂuence the study’s success.
Deﬁning the endpoint comprises identifying a particular
method for the patient assessments obtained at one or more
speciﬁed times during the study and a stated statistical method
for conducting analysis to provide a comparison between groups.
The assessment itself, in isolation from the other speciﬁed endpoint
elements, is not the endpoint. This is important to recognize because
other aspects of an endpoint, for example, number of evaluations,
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interpretation of the study results.
Some patient assessments commonly used in medical care
will be suitable for use as outcome assessments; some will not. A
patient’s medical status is evaluated multiple times in various
ways for various reasons in clinical care (diagnosis, estimating
prognosis, monitoring of response, etc.). Particular assessments
are often suited to particular purposes. For example, often
substantial medical experience led to an understanding of how
the new presence or absence of a speciﬁc clinical sign or
symptom before treatment aids in diagnosing a particular dis-
ease. The presence or absence of this clinical sign indicates that
the patient is at risk for the disease’s known effects.
In contrast, the treatment beneﬁt after diagnosis and treat-
ment is a reduction in or an avoidance of the disease’s important
effect(s). In many diseases, however, there is often insufﬁcient
medical experience to demonstrate that elimination of a
particular diagnostic sign after the administration of an inter-
vention reliably indicates that the patient will avoid a particular
adverse consequence of the disease. Therefore, this particular
diagnostic sign would not be a good assessment to use in an
endpoint.Identiﬁcation of the Intended Treatment Beneﬁt
As stated above, a treatment beneﬁt is a favorable effect on a
meaningful aspect of how a patient feels or functions in his or
her typical life (or on survival). In many diseases, a single
manifestation may impair or prevent multiple related activities
that are part of the patient’s normal life. This impairment is
meaningful to the patient. These closely-related affected activ-
ities, as a group, can be thought of as an aspect of how a patient
functions in his or her life. Identifying this grouping is a uniﬁed
abstraction or conceptualization of an aspect of a person’s life
adversely affected by the disease.
A disease affecting arm motion, for example, multiple scle-
rosis or Parkinson disease, may directly diminish a patient’s
ability to perform many activities dependent on arm motion,
such as dressing, eating, or toileting. This group of affected
functional abilities might be conceptually identiﬁed by the term
“upper limb–dependent personal activities” (or similar phrasing
selected by the developer) to obviate the need to repeatedly list
the various activities that are affected. A treatment that favorably
affects this inherently meaningful aspect of a patient’s life is
clearly providing a treatment beneﬁt.
As another example, patients affected with lower limb weak-
ness may have a problem in walking from a bus stop to their
ofﬁce, walking around a shopping mall, a grocery store, or within
their own house. These and many similar activities are a
common part of a typical healthy person’s life. An abstracted
commonality of these activities might be named “ambulatory
performance.” The inability to perform any of the individual
activities is meaningful to the person who cannot do so. A
treatment that improved patients’ ability to walk from the bus
stop to their work ofﬁce because of increased lower limb strength
would be expected to have beneﬁcial effects on similar activities
that rely on walking as well. A treatment that improved the
activities within this aspect of a person’s life would be a mean-
ingful beneﬁt, that is, a treatment beneﬁt on ambulation.
In some cases, an important effect of the disease can be
named with less abstraction than these examples. For instance,
pain is an important adverse feature of metastatic breast or
prostate cancer in some patients. Palliation of pain (pain relief)
would be an important treatment beneﬁt.
For many diseases, there are several separable groups of
related activities (functional abilities) affected by the disease.These functional abilities may have more commonality within
the group than between groupings, for example, ambulation
activities versus hand and arm–dependent activities versus
cognition-based activities. Each group identiﬁes an abstracted
concept of a distinct and meaningful aspect of health that is affected
by the disease. Improving the ability to carry out activities in one,
or more than one, of these separate aspects of health would be a
treatment beneﬁt.
The meaningful health aspect that is the intended treatment
beneﬁt should be identiﬁed with phrasing that promotes clear
communication during the development period of an outcome
assessment to be used in a study endpoint. The identifying
phrase used for the meaningful health aspect should provide
clarity to the people involved during the outcome assessment
development period and to those who may consider the outcome
assessment for use in clinical trials, for example, investigators,
study designers, and regulatory agency staff, regarding the
intended beneﬁt that would be shown with an effective therapy.
Clearly stating the treatment beneﬁt intended to be shown
with the outcome assessment is essential during the develop-
ment process. Understanding the relationship between the out-
come assessment’s measurements and the speciﬁc intended
meaningful health aspect is a critical part of good measurement
practices (J.H. Powers, D.L. Patrick, M.K. Walton, et al., unpub-
lished report). Furthermore, clear identiﬁcation of the meaningful
health aspect is crucial for treatment beneﬁt communication for
therapies that have gained regulatory agency approval.
It should be noted that phrasing to describe the treatment
beneﬁt in drug labeling is based on consideration of all demon-
strated beneﬁts across several endpoints after the study is
completed. Nonetheless, the description is based on the known
relationship of an identiﬁed meaningful health aspect with each
of the outcome assessments in study endpoints.
Because diseases have multiple manifestations affecting dif-
ferent types of patient functioning (or feeling), for example, leg
weakness, cognitive impairment, respiratory impairment, and
pain, that adversely affect patients, there can be multiple health
aspects that could be appropriate as separate intended treatment
beneﬁts. Each meaningful health aspect needs to be demon-
strated by a distinct outcome assessment and clinical study
endpoint.
In some cases, combining several separate aspects of health
into an overarching single health concept will be appropriate. For
example, some degenerative neurologic diseases damage the
patient’s ability to use both upper and lower limbs for typical
activities of life and impair cognitive function. The separate
groups of impaired function deﬁne separate meaningful aspects
of health that a treatment might beneﬁt. A comprehensive
treatment beneﬁt, however, might be intended, and named as
an effect on “disability of disease X.” Nonetheless, identiﬁcation
of the speciﬁc impaired functional abilities, for example, disabil-
ity in personal activities using the upper limbs, disability in
ambulation, and disability in cognitive activities, is needed to
adequately identify the intended beneﬁt and determine whether
several outcome assessments are needed to evaluate the several
components of meaningful health aspects.
If several outcome assessments are combined into a single
composite endpoint, the endpoint should be formed carefully.
The endpoint structure should allow analysis of the individual
component assessments and how each contributed to the com-
posite result. This will promote understanding which beneﬁts
were shown to be associated with treatment.
An important principle to keep in mind when developing
therapies for multifaceted diseases is the different levels of
importance to the patient of different health aspects. Some are
more signiﬁcant or of higher importance to the patient than are
others. Moreover, not all disease manifestations are amenable to
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should consider the range of meaningful health aspects related to
the disease and select for study the one(s) that the therapy may
beneﬁt and is of sufﬁcient importance to the patient to warrant
assessment in a clinical trial.Specific Feelings or Activities
Occurring in a Person’s Typical
Life
Specific Outcome
Assessment
Fig. 1 – Relationship of concepts with an outcome
assessment. When planning a clinical trial, investigators
select a group of related feelings or activities that can occur
in patient’s typical lives, are adversely affected by a disease,
and are expected to show beneﬁt from the intervention. The
group of feelings or functions is identiﬁed as a speciﬁc
conceptualized meaningful aspect of health. If the selected
group of feelings or functions is not planned for direct
measurement, a concept of interest that is thought
measurable and substantially inﬂuences the meaningful
aspect of health is formulated. The measurement of the
concept of interest is operationalized as a speciﬁc, well-
deﬁned, clinical outcome assessment. An interplay may
occur between selection of the meaningful aspect of health
and the concept of interest as investigators reﬁne them to
have a concept of interest for measurement that is thought
both informative of the meaningful aspect of health and has
a practical means to be measured (the speciﬁc clinical
outcome assessment). In some cases, the affected feelings or
functions affected by the disease are intended to be directly
measured, and the concept of interest for measurement is
identical to the meaningful health aspect.The Measured concept of interest (COI): A Practical
Approach to Evaluating How Patients Feel and
Function
In a clinical trial, the outcome assessment is the speciﬁc method
to obtain a measurement used in a study endpoint. The results
are analyzed leading to a conclusion regarding whether a treat-
ment beneﬁt on the selected meaningful health aspect has
occurred. Selecting an assessment for a study endpoint warrants
attention to whether the assessment directly describes or can be
shown to have a relationship with (indirectly describe) a treat-
ment beneﬁt for the disease. Often, patient reported outcome
(PRO) instruments are used to directly measure the meaningful
health aspect. In many disorders, however, an appropriate PRO
instrument has not been developed or directly measuring the
relevant daily functioning is difﬁcult, for example, in persons
who cannot report for themselves [22,23,25].
In these circumstances, investigators interested in an evalua-
tion of certain functional abilities may instead deconstruct the
meaningful health aspect activities into simpler (more narrowly
deﬁned) bodily abilities. These abilities are thought to be relied
upon when doing meaningful health aspect activities. One of
these abilities may be hypothesized as both well related to many
activities within the meaningful health aspect and more readily
measured, for example, leg strength in impaired walking diseases
or short-term memory in certain dementia disorders. The con-
ceptualized simpliﬁed bodily activity may then be selected as an
opportunity to create a practical measurement tool for studying a
treatment. The conceptualized simpliﬁed bodily activity is called
the concept of interest (COI) for measurement (Fig. 1).
In the example of pain as the meaningful health aspect, the full
experience of pain has multiple conceptual facets or character-
istics. These include intensity, duration, frequency, and quality (e.
g., quality described as sharp, burning, or shooting). The pain
experience arising from different disorders can differ in these
characteristics. Consequently, when pain is the meaningful health
aspect, investigators might select different pain characteristics as
the COI. In a particular disorder, pain intensity might be selected as
the pain attribute to be measured, whereas in a different disorder,
pain frequency might be selected as the COI for measurement.
It is important to recognize that in all studies there must be a
targeted COI for the actual measurement. Furthermore, it may or
may not be the meaningful health aspect. When a PRO is the
outcome assessment, the COI for measurement usually is the
meaningful health aspect—the COI is identical to the meaningful
health aspect. This is efﬁcient when the meaningful health
aspect can be measured directly with a valid instrument. It is
also necessary if the meaningful health aspect, such as a
patient’s feelings, can be evaluated only directly—by the patient.
Nonetheless, in many studies, the COI for measurement is not
the same as the meaningful health aspect. Moreover, frequently,
there are multiple COIs that might be useful in understanding
whether a treatment beneﬁt on the selected meaningful health
aspect has occurred. Investigators must select one (Fig. 2) for a
measurement to form the basis of an endpoint. In these circum-
stances, clearly identifying the COI can aid developing the out-
come assessment and establishing that it has validity for the
intended use and interpretation.
The method of measurement is a procedure that produces a
categorical rating or continuous score that is intended torepresent the measured COI, that is, an operationalized expres-
sion of the COI. For example, pain intensity may be measured in
multiple ways. A measurement tool might ask patients to 1)
select a score between 0 and 10 depicting their current pain
intensity, 2) score the average pain intensity over the past
month, or 3) maintain a diary of the number of analgesic pills
used each day.
These distinct speciﬁcally deﬁned potential methods to meas-
ure the COI are not necessarily equivalent. They might provide
different results in a clinical trial owing to measuring distinct
aspects of the pain experience or having different measurement
properties. For example, reliability may be different for pain
scores using a 1-month recall period compared with a rating of
current pain. Alternatively, the interpretation of the measure-
ment may be not inherently clear; for example, a pill count might
relate to pain relief duration from each pill or it might relate to
how frequently pain intensity is beyond a patient’s personal
threshold. Differences in measurement properties can also affect
the assessment’s suitability for the speciﬁc circumstances of use.
(See “Context of Use” section.)
Once the outcome assessment’s interpretation is under-
stood, evaluation of measurement properties can begin. This
step is essential if developing or choosing an outcome assess-
ment for a clinical trial to ensure that the assessment is valid
and suitable for the intended use. The measurement properties
and principles for evaluating outcome assessment measure-
ment properties to determine their suitability is beyond
the scope of this discussion but has been discussed by others
[21–23,25–28].
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Fig. 2 – Relationships of meaningful functions with an indirect outcome assessment measure. A group of related activities
meaningful to the patient (red rectangular box, Speciﬁc Meaningful Activities) is identiﬁed that would be a treatment beneﬁt to
the patient if improved by an intervention. A name is given to the meaningful health aspect that identiﬁes the abstracted
concept of the grouping (blue oval, Ambulation-Dependent Function). This speciﬁc type of function is just one from among the
range of meaningful areas of feeling or functioning (blue ovals) in which patients with the disease might desire a treatment
beneﬁt. Each individual meaningful health aspect is a speciﬁc portion of the comprehensive range of all the meaningful
feelings and functions affected by the disease any of which might be intended treatment beneﬁt and evaluated in a clinical
trial. In this example, Ambulation-Dependent function has been selected as the potential treatment beneﬁt to be studied.
Speciﬁc meaningful activities associated with the nonselected health aspects are not illustrated. Evaluation of the identiﬁed
activities might be directly assessed in a deﬁned outcome assessment (e.g., a PRO, not shown). The concept of interest for
measurement in that case would be identical to the identiﬁed meaningful health aspect (see Fig. 1). The selected meaningful
health aspect might instead be deconstructed into narrowly deﬁned concepts of interest that are thought to be important in
performing the meaningful activities (COIs, orange ovals). Procedures could be devised as speciﬁed clinical outcome
assessment (COA) instruments to represent a measurement of the COI (deﬁned COAs, green boxes). In this example,
performance outcome (PerfO) tools are shown for each COI, but other PerfOs and other types of COAs could be developed for
any of the COIs (see Fig. 3). The PerfO procedure, an operationalized method to measure a body action identiﬁed as the COI, is
a task that is not a part of a person’s usual normal life. The COA provides a score for the observed quality or quantity of
performing the procedure and is used to form a study endpoint. The meaning of score or change in score to a person’s typical
life is not intrinsically precisely known, but is hypothesized to reﬂect the meaningful functional activities. The actual meaning
of a speciﬁc score (or change) to the patient cannot be known from the description of the PerfO procedure alone and should be
evaluated in the process of developing the instrument. Dashed outline boxes name the type of concept or category of activity
illustrated in that region of the ﬁgure, as presented in Figure 1. Ovals name speciﬁc concepts: either meaningful health
aspects (blue) or COIs (orange). Solid outline boxes name speciﬁc functional activities of typical daily life that are meaningful
(red box group), or speciﬁc procedures each of which might be developed as a COA (green boxes) to measure the selected COI.
Short arrows not leading to a concept or a COA indicate that other possibilities exist, but are not shown. COI, concept of
interest; PRO, patient reported outcome. (Color illustration of ﬁgure appears online.)
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ability to 1) detect a treatment effect and 2) interpret the effect as
a treatment beneﬁt. The outcome assessment’s relationship with
the meaningful health aspect should be understood before using
the outcome assessment in an endpoint of a clinical trial. One of
the important steps in ensuring that a new outcome assessment
is suitable for demonstrating a treatment beneﬁt is to conﬁrm the
hypothesis that the outcome assessment is well related to the
meaningful health aspect. Differences in the outcome assess-
ment should be reﬂective of changes in the meaningful healthaspect. Even when the COI is identical to the meaningful health
aspect, the relationship between the outcome assessment (as a
speciﬁc implementation of the COI) and the meaningful health
aspect should be examined.Context of Use: Important Clinical Trial Factors
Clinical studies are conducted in a speciﬁc population with a
delineated study design, set of procedures, including details on
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endpoint. These study design features, taken together, are called
the context of use (COU). The COU describes the outcomes assess-
ment setting and manner of use. The importance of the COU has
been highlighted by the FDA [29].
The COU should be clearly stated at the outset of development
for a new outcome assessment or evaluation of an existing
outcome assessment [22,23]. Outcome assessment measurement
properties can be affected by factors deﬁned in the COU. A
comprehensive description of the COU will help ensure that a
suitable outcome assessment is developed for the trial’s speciﬁc
application.
It should be noted that changes in the study design and/or
other study elements can substantially affect the outcome
assessment’s performance characteristics [30,31]. When an out-
come assessment will be applied in a changed COU, the revised
COU should be clearly described. These changes can go so far as
to alter the interpretation of the trial’s results. Reevaluation of
the outcome assessment properties in the new COU is advisable.
Important components for creating a well-deﬁned COU may
include the following:1. Disease of study: The disease of interest should be clearly
deﬁned, for example, using diagnostic criteria. The disease’s
important effects on the patient should be well described to
ensure that the stated meaningful health aspect is relevant
for the disease. It is also important to identify whether the
study participants have the disease at study enrollment or
whether they are at risk of developing the disease, that is,
whether the therapy is for treatment or prevention of the
disease.2. Patient subpopulations: Many diseases are heterogeneous
between patients and change over time within a patient.
The precise disease subpopulation intended as the target
population should be identiﬁed. A wide range of factors may
be important to distinguish or differentiate these patients,
such as 1) the phenotype (or subtype) of the disease; 2) the
patient-speciﬁc disease characteristics (severity, duration,
involvement of speciﬁc portions of the body); 3) demographic
characteristics of the intended patients (age, race, ethnicity);
4) history of previous treatments; 5) comorbidities; or 6) other
factors that might be used as trial entry or exclusion criteria.3. Cultural, language, or other geography-related factors: Many
outcome assessments rely on questioning patients to obtain
the primary input for the outcome assessment results. Thus,
when multiple languages are used across a study population,
it is important to determine whether the questions have the
same meaning in each of the different languages. Some
questions can invoke cultural variations, for example, differ-
ences in what factors are taken into consideration by patients
in their responses. Furthermore, there can be cultural inﬂu-
ences affecting the relationship between the COI and mean-
ingful health aspect. This relationship can vary across cultural
settings in which the outcome assessment is used. To ensure
study results remain interpretable, these factors need to be
considered. For more information on this topic, please see
ISPOR’s two PRO task force reports on translation and linguis-
tic validation [32,33].4. Standard concomitant care: Clinical trials commonly allow
some existing therapies to be administered along with the
investigational intervention when they are part of standard
clinical practice and that care can affect the disease course.
If the outcome assessment was developed in a time period
before the use of the concomitant therapies allowed in a
new clinical study, the outcome assessment’s measurement
properties can be affected and, therefore, be different than
expected. Disparities in measurement properties betweenstudy sites can arise if these properties were evaluated with
only a subset of the study-permitted choices for concom-
itant care and care varies across clinical sites, for example,
in different global regions. Therefore, the intended choices
for standard of care should be identiﬁed as part of the
COU and these issues should be kept in mind when
developing a new or evaluating an existing outcomes
assessment.5. Endpoint positioning: Endpoint positioning is twofold. It
describes where the endpoint using the outcome assessment
falls within the study objectives (as shown by the analysis
plans for the study) and the regulatory role the endpoint is
intended to support. An outcome assessment may be appro-
priate in one context and not appropriate in another. For
example, it could support marketing approval decisions in one
context of use, providing appropriate evidence for the central
efﬁcacy claim in a particular disease. It might, however, be
appropriate only for supplementary claims of efﬁcacy in a
different COU. Some outcome assessments are not appropri-
ate to support any efﬁcacy claim. Specifying the objective and
the regulatory role of an endpoint is thus an important
element of the COU.6. Manner of use within the endpoint: An outcome assessment
is one of the elements of an end point. It may be incorporated
into the endpoint and data analysis in various ways in differ-
ent clinical trials. There may be differences in the number of
times the outcome assessment is measured during the study
and used in the endpoint. Alternatively, there may be differ-
ences in the time points (timing) of assessment during the
study. In addition, there are several options for an endpoint
analysis method, such as 1) the group average outcome
assessment value at a speciﬁc time point in the study, 2) the
percentage of patients who are responders at a speciﬁc time
point by meeting speciﬁed outcome assessment criteria, 3)
repeated measures using several time points during the study,
or 4) time to event. Distinct ways of using the outcome
assessment in an endpoint yield different summarizations
of patient experience during the study. These distinct uses
can translate to different relationships with the meaningful
health aspect. The number and timing of outcome assess-
ment measurements along with the analysis method should
be speciﬁed as part of the COU.7. Measurement setting: Outcome assessments can be obtained
in various settings—in a home, an outpatient clinic, or a
hospital inpatient setting, among others. These distinct set-
tings can alter the actual measurement obtained, and thus the
measurement properties of the outcome assessment. There-
fore, the measurement setting should be stated as part of
the COU.8. Method of outcome assessment administration: Outcome
assessments can be designed for more than one mode or
method of administration [34]. There are options for 1) who
administers the outcome assessment, for example, self-
administration, an otherwise untrained person, or a trained
professional, and 2) how it is administered, for example,
visual versus auditory, face-to-face versus by telephone, and
electronic versus nonelectronic. It is crucial to clearly
specify the mode(s) and/or method(s) of administration of
the COU.
Differences in administration can affect the data obtained,
and thus alter the measurement properties of outcome assess-
ment. This can be particularly problematic if multiple options are
used within a single trial but have not been shown to provide
equivalent measurement properties of the outcome assessment.
If another mode or method of administration is introduced,
equivalence needs to be demonstrated. For more information
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measurement equivalence and mixed modes data collection
[34,35].Attributes of an Outcome Assessment
Although the COU describes the setting and manner of use of an
outcome assessment, it does “not” deﬁne the outcome assess-
ment. A careful and complete deﬁnition of the outcome assess-
ment will include a precise description of the procedure for
obtaining the measurement. Detail is needed to evaluate,
develop, and use the assessment in clinical trials. The deﬁnition
determines certain distinguishing attributes (illustrated in Fig. 3)
that inﬂuence the measurement properties and how the meas-
urement properties are evaluated.Concept of Interest
to be Measured
Specific Outcome
Assessment
Clinical Outcome
Assessment (COA)
Indirect Measure of
Meaningful Health
Aspect
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Fig. 3 – Attributes of outcome assessments. A speciﬁc
outcome assessment is selected or created to operationalize
measurement of the concept of interest. Outcome
assessments are of two major types: clinical outcome
assessments and biomarkers. Clinical outcome assessments
have an attribute identifying the type of person whose
judgment can inﬂuence the reported measurement. Clinical
outcome assessments may be inﬂuenced by the judgment of
the patient, clinician, or a nonclinician observer; they may
also be a nonjudged recording of a task performed by the
patient (performance outcome). Clinical outcome
assessments may be directly reporting the meaningful
feelings or functions selected as the potential treatment
beneﬁt, or may be reporting measurements that are thought
to be indirectly informative regarding those feelings or
functions (see Fig. 1). Biomarkers can only indirectly
measure the meaningful aspect of health.Important Outcome Assessment Attributes
Attribute 1: Is the outcome assessment dependent on patient’s
active involvement or rater’s judgment?
Clinical assessments (evaluations) depend on the patient or another
person, for example, a trained medical professional, spouse,
caregiver, or teacher, to integrate observations, transform them
into a rating, and record (report) the result (measurement). Clinical
assessments are evaluations that are susceptible to variation
unrelated to the patient’s true clinical status owing to 1) variation
in patient volition (which can cause rating differences for an
individual patient between successive administrations or between
patients) or 2) dependence on the judgment of a rater. A clinical
assessment used to measure patient outcome in a clinical trial is
called a clinical outcome assessment (COA).
Clinical assessments are susceptible to both sources of varia-
tion. Some patient assessments require the patient’s active
involvement to create a record (physical or electronic) and/or to
perform an activity that is the basis of the rating or score. The
process of creating the record or performing the activity is
inﬂuenced by patient volition and motivation to participate in
the assessment. The level of motivation and attention to the
assessment process may vary over time within a patient or differ
systematically between patients. Such variation can yield differ-
ences in ratings or scores unrelated to differences in the under-
lying medical status of interest (symptom or functional ability).
These variations can potentially affect the measurement proper-
ties of the outcome assessment.
Variability is inherent in a measurement dependent on a
rater, whether it is the patient (self-observation) or another
person using judgment to make a rating. Raters other than the
patient may apply judgment on 1) the patient’s response to an
inquiry, 2) observations on patient’s task performance, or 3) the
relative weighting among several observations in determining
the rating. Rater judgement may be inﬂuenced by prior experi-
ences and biases of the rater that can lead to scoring differences
between raters unrelated to differences in patients’ medical
status. Wide disparities in how the rater’s judgment affects the
ﬁnal rating can damage the COA’s validity or decrease its
reliability.
Although there can be patient or rater inﬂuence on measure-
ments unrelated to the patient’s medical status, COAs can be
developed with assurance that they are well deﬁned and reliable
within the target COU. Such COAs can be highly informative
regarding patients’ medical status and reveal treatment effects
with meaning to patients on a very broad range of treatment
beneﬁts.
A biomarker assessment, in contrast, is one that is subject to
little to no patient motivational or rater judgmental inﬂuence. (A
Biomarkers Deﬁnitions Working Group [36] has worked on issues
involved with biomarkers used in surrogate endpoints, and
deﬁned biomarker for that discussion. The characterization of
biomarker in the present discussion [focused on clinical assess-
ments] differs from the working group’s to better ensure distin-
guishing biomarkers and clinical assessments. This distinction
used in this report is important when addressing the range of
COA types and complexities that arise when developing clinical
assessments for use in endpoints.) Examples include protein
levels in blood or urine measured by standardized methods or
an automated quantitative size measurement of a pathologic
lesion visualized with magnetic resonance imaging.
It can be noted that many biomarkers are included within
what are often called “clinical laboratory measurements” in
clinical practice or clinical trial protocols. Nonetheless, such
laboratory measurements of substances physically present in
body ﬂuids are not clinical assessments as deﬁned in the frame-
work described here because they are not subject to the
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the term “clinical assessment” in this framework is narrowed
from the general language meaning of “concerned with or
involving patients” so as to distinguish these assessments from
biomarkers.Attribute 2: Who Is the rater? Which type of rater applies
judgment to form the measurement?
The rater is the person who obtains the information during the
assessment procedure and applies judgment to what he or she
has heard or observed to form a rating that is recorded (reported)
as the measurement. Although there are many different people
who may be involved in performing assessment of patients in a
clinical trial, for purposes of this COA discussion, we use three
rater categories: 1) patients; 2) clinicians (deﬁned as those using
professional judgment for patient assessments, e.g., investigators
and nurses); and 3) nonclinician observers. Because people with
different backgrounds, experience, and training are likely to have
different perspectives and skills, their judgments may differ and
have a large impact on the rating. There is a fourth category of
clinical outcome assessment that is considered a COA that does
not involve rater judgment but does rely on patients’ active
involvement, and thus is not a biomarker (Fig. 3).
When appropriately deﬁned, developed, and evaluated, any of
these four categories of COAs can become accepted as a well-
deﬁned and reliable COA and suitable for use in a clinical trial
endpoint. Which type of COA is more advantageous for a
particular COI is strongly inﬂuenced by the speciﬁc intended
context of use and should be carefully considered at the outset of
developing a new COA or evaluating an existing COA.
PRO assessments are those in which the patient is the rater.
PRO assessments rely on a patient’s direct responses to ques-
tions. These responses may be recorded by the patient in various
ways such as on paper, via computerized questionnaire forms, or
via interviews in which the patient’s observations or reports are
recorded exactly as spoken, without any interpretation (judg-
ment) on the part of the interviewer. Because a patient’s direct
report can capture a wide range of feelings and functions, as well
as provide a direct measurement of how a patient feels, for
example, pain or low mood, there has been increasing interest in
developing PRO COAs. FDA guidance on the topic [24] has high-
lighted the regulatory agency’s interest in these instruments.
Clinician reported outcome (ClinRO) assessments are those in
which a member of the investigator team with appropriate
professional training is the rater. A clinician applies professional
expertise and judgment to the observations of, or conversations
with, the patient to arrive at a rating according to the COA’s
deﬁnition. For example, a ClinRO assessment may call for the
clinician to interpret the patient’s responses to questions in an
interview, judge the quality of patient’s actions, or judge ﬁndings
of a physical examination. A ClinRO assessment is any COA in
which the individual determining the rating must have some
speciﬁc professional training to properly form a judgment. Note
that although all ClinRO outcome assessments are COAs, not all
COAs are ClinROs. The distinction is between clinical (attribute 1)
and clinician (a speciﬁc type of reporter).
Observer reported outcome (ObsRO) assessments are those in
which observations can be made, appraised, and recorded by a
person other than the patient and do not require specialized
professional training. The rating is nonetheless inﬂuenced by the
perspective of the observer. These include COAs that are best
made by a companion, for example, parent, spouse, or caregiver
of the patient. The observer rater is often taught what to observe
and judge to form the rating, but health care professional training
is not needed. The term observer rater is used in this narrowed
sense to contrast with clinical professionals who must alsointeract with and observe the patient when performing ClinRO
assessments.
Performance outcomes (PerfOs) are a type of COA in which the
patient is assessed but no rater judgment affects the measure-
ment. It is based on the patient’s performance of a deﬁned task
that is quantiﬁed in a speciﬁed way that does not rely on
judgment to determine the rating. PerfOs include instruments
such as the distance walked in 6 minutes and the number of
pictorial symbols correctly matched to a key within a ﬁxed
amount of time. Although a clinician or observer is administering
and monitoring the performance of the PerfO assessment task,
this individual does not apply judgment to quantify the perform-
ance. These assessments are still categorized as COAs because a
patient’s motivation or volition is involved in the performance of
the task.
Because PerfOs are typically evaluated in the health care clinic
setting but do not rely on a rater’s judgment for the score, they
can often be designed to have good reliability, rendering them
attractive for many multicenter clinical trials in disorders in
which physical function activities are the meaningful health
aspect for treatment beneﬁt. PerfOs are usually not measuring
the intended meaningful function activities, however, and are
instead usually designed to measure a COI that is thought
informative of the meaningful functions (Fig. 2).Attribute 3: Is the outcome assessment directly measuring a
meaningful aspect of how the patient feels or functions?
COA instruments that provide direct evidence about the mean-
ingful health aspect are termed direct measure COAs. In some
studies, the COA of the endpoint is directly assessing the mean-
ingful health aspect so that observed treatment effects are
inherently interpretable as showing meaningful beneﬁt. Many,
but not all, PRO instruments are intended to have this
interpretability.
Indirect measure COAs are assessing a related, measurable COI
(Fig. 3). The interpretation of indirect assessments is not inher-
ently clear with regard to the intended meaningful health aspect.
A well-deﬁned relationship between the outcome assessment
and the meaningful health aspect enables interpreting a favor-
able effect on the endpoint as a favorable effect on the mean-
ingful health aspect (i.e., as a treatment beneﬁt).
Recognizing whether the COA is a direct or an indirect
measure of the meaningful health aspect is important for
determining whether evidence to establish the relationship
between the measurements of the COI and the meaningful health
aspect is necessary.
The graded quality of indirectness is important to recognize.
Some COAs measure abilities or actions representing a COI that is
close, but not identical, to how the patient functions in typical
life. Examples include some in-clinic performance instruments
that simulate activities of daily living [37], or visual acuity testing.
These COAs are measurements that are close to evaluating the
meaningful health aspect itself. Other COAs measure COIs that
are substantially unlike the patient’s functioning in daily life (e.g.,
supine quadriceps isometric strength). Interpreting changes or
differences in indirect COAs are dependent on additional evi-
dence that clearly deﬁnes the relationship between the COA’s
measurement and the meaningful health aspect (see discussion
of measurement principles in J.H. Powers, D.L. Patrick, M.K.
Walton, et al., unpublished report).
For indirect measure COAs, the degree of indirectness
between the COI and the meaningful health aspect will guide
the amount and type of evidence that should be obtained during
the course of developing and evaluating the COA in accordance
with good measurement practices (J.H. Powers, D.L. Patrick, M.K.
Walton, et al., unpublished report). Establishing the relationship
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the meaningful health aspect for a COA that is closely similar to a
patient’s functioning in typical life will generally be more
straightforward than for a COA that is substantially dissimilar
to a patient’s typical life activities.
This consideration is also relevant to biomarkers that are
generally very distant from the actual meaningful health aspect.
Substantial amounts of evidence are needed to establish the
relationship between a biomarker and the meaningful aspect of
feeling or functioning to support use of the biomarker to dem-
onstrate a treatment beneﬁt. When sufﬁcient evidence is avail-
able, however, biomarkers can be very valuable and used in
surrogate endpoints, for example, blood pressure for many
hypertension treatments or hemoglobin A1c levels for some
diabetes treatments.Effect of Context of Use on Measurement Properties
The suitability of a COA for a particular clinical trial is dependent
on its measurement properties as used in a speciﬁed endpoint for
the trial. As stated previously, those measurement properties can
be affected by several factors, such as the speciﬁc COU and the
procedures used in performing the assessment. The COU can
affect whether the outcome assessment measurement of the COI
is adequately related to the intended meaningful health aspect,
as well as the measurement properties of the outcome assess-
ment such as reliability and ability to detect change.
Even within the spectrum of a single disease, the elements of
the COU can alter the interpretability of an observed treatment
effect. A treatment effect that is a modest fraction of the full
dynamic range of a COA might be of clinical value to patients at a
mildly affected stage of a disease, but not important to patients at
a severely affected stage of the same disease.
The ability of the endpoint to detect change may be different
for clinical studies with different design features. A COA that
shows a good dynamic range for one patient subpopulation may
have an unacceptable ceiling or ﬂoor limitation in a different part
of the overall disease population. In a study intending to show a
treatment beneﬁt as reducing patients’ decline (reduction in
worsening of the disease) where slow progressive worsening is
the natural disease course, a COA’s reliability may be adequate to
detect a treatment effect in a 1-year trial. However, it may not be
adequate to demonstrate the treatment effect in a study of 3-
month duration that is the same size as the 1-year trial.
Similarly, a COA suitable for one context of use might not be
valid when a different disease is studied even if the intended
meaningful health aspect does not change. For example, a COI
(measured by a COA) closely linked to the meaningful health
aspect in one disease may be poorly linked in another disease
because other features of the second disease diminish the
inﬂuence of the COI on the meaningful health aspect.Identifying the COA
Similar to explicitly identifying the intended treatment beneﬁt,
COAs need to be clearly identiﬁed both in name and in descrip-
tion. Because the COA’s measurement properties and suitability
for a clinical trial can vary with the speciﬁc COU, the COU should
also be clearly described when developing and evaluating a COA.
New COAs should be given an appropriate name, such as
indicating the task performed for a PerfO assessment or the
intended COI for a ClinRO assessment. Furthermore, when COAs
are revised for a new context (COU), version should be clear.
There are long-standing COAs in which the procedures have
changed over time as different investigators use the COA indifferent studies. Frequently, modiﬁcations are not stated in
study reports; for example, the version and the details of the
COA were not described [38]. Thus, studies that appear to use the
same COA may in fact have used distinctly different instruments.
To avoid this confusion in evaluating or using a COA, it is
important to use clear and informative names for new COAs
and identify the version of an existing assessment.
For assessments that directly measure the meaningful health
aspect, this may be clear from the description of the measure-
ment procedure. Unfortunately, intrinsic clarity regarding the
intended meaningful aspect of health is seldom the case for
indirect assessments. Therefore, the intended meaningful health
aspect should be explicitly identiﬁed for all assessments, irre-
spective of whether it seems implicitly clear.
Finally, it is essential to evaluate an existing COA planned for
critical study endpoints to determine whether there is sufﬁcient
information to establish the relationship with the meaningful
health aspect. The name itself does not support the conclusion
that it is a good measurement of that meaningful health aspect.
For example, a COA named “Disease X Disability Scale” does not
alone ensure that it is a good measurement of “disability” for
disease X or for any other disease. The recommended approaches
are as follows: In an existing COA, evaluate the evidence to
determine whether there is a well-deﬁned relationship with the
meaningful health aspect. In a new COA, name it to reﬂect what
is actually measured and separately name the intended mean-
ingful health aspect.Conclusions
The beneﬁt of medical interventions is generally demonstrated
by controlled clinical trials of the intervention that show favor-
able effects on the efﬁcacy endpoints. A successful clinical trial
depends on many factors, among them, the availability of good
outcome assessments to use in deﬁning study endpoints.
Demonstrating beneﬁt in a disease may require the develop-
ment of a patient assessment that does not already exist or the
careful reevaluation of an assessment that has not yet been
shown to be well deﬁned, reliable, and interpretable for studies of
the speciﬁc disease. Development of a new assessment may also
be needed to support 1) an improved endpoint that is capable of
demonstrating the advantage of a new therapy over an existing
one or 2) a new endpoint to evaluate treatment effect on an
aspect of the disease that has not previously been evaluated.
An effect on an endpoint needs to be interpretable as a
meaningful effect for patients, that is, a positive effect on how
patients feel, function, or survive. A study endpoint is built on an
outcome assessment (most commonly clinical assessments). It is
intended to represent the meaningful health aspect when used in
a well-speciﬁed context (COU). A COA measures a concept of
interest that may either 1) directly measure the meaningful
health aspect or 2) measure a COI thought to have a strong
relationship with the meaningful health aspect and is more
readily measured.
The ﬁrst step to understanding the performance properties of
an outcome assessment in a COU is to identify the attributes of
the outcome assessment, particularly those discussed in this
report. All outcome assessments can be categorized by 1)
whether patient volition/motivation or rater judgment deter-
mines the rating or score; 2) the type of rater applying judgment
(the patient, a clinician, an observer) or a PerfO in which no rater
judgment enters into the rating; and ﬁnally, 3) whether the
intended meaningful health aspect is directly assessed or indi-
rectly assessed.
Categorizing an outcome assessment by these attributes can
aid investigators in the work of developing and evaluating a COA.
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specifying the detailed procedure for conducting the assessment,
2) determining how to evaluate whether the outcome assessment
is well deﬁned and reliable, and 3) reﬁning the outcome assess-
ment during the course of its development for a speciﬁc COU.
Assessing whether a COA is well-deﬁned and reliable and
suitable for a planned clinical trial also necessitates 1) clearly
and fully identifying the new COA with an appropriate name, or if
an existing COA is used, include the version and 2) providing a
detailed explanation of the intended meaningful health aspect,
the COI measured, and the COU.
The concepts and terminology presented in this article can aid
in clearly describing and effectively developing or evaluating
COAs. Many of these COA features may not have been not well
speciﬁed for older COAs. This does not mean that these older
COAs are invalid and unsuitable for further use. Instead, inves-
tigators should recognize that the characteristics of an older COA
may not be completely understood and need further evaluation.
Investigators should consider this during the COA selection
process. If investigators determine that substantial COA develop-
ment or evaluation is needed for a future clinical trial, this effort
should be initiated well in advance of ﬁnalizing the study design.
Following these recommendations can lead to improved COAs
and better study endpoints, enabling more informative and
efﬁcient clinical trials.Glossary
Brief summary deﬁnitions; see text for full explanation.
Biomarker: A patient assessment that is not inﬂuenced by the
patient’s motivation or volition or a rater’s judgment. Com-
mon types of biomarkers are biochemical measurements of
blood and quantitative measurements of radiographic images.
Clinical Assessment: An assessment that is susceptible to
variation unrelated to the patient’s true clinical status owing
to 1) variation in patient volition (which may cause rating
differences for an individual patient between successive
administrations or between patients), or 2) dependence on
the judgment of a rater (which may differ between raters
owing to differing experiences or perspective).
Clinical Outcome Assessment (COA): A clinical assessment
instrument that is used as the measure of patient outcome
in a clinical trial. There are four types: PRO, ClinRO, ObsRO,
and PerfO.
Clinician Reported Outcome (ClinRO): A type of COA in which a
member of the investigator team is the rater. The investiga-
tor’s professional training is relied upon to judge what rating
or score will be reported. All ClinROs are COAs, but all COAs
are not ClinROs.
Concept of Interest (COI) for Measurement: The concept that the
outcome assessment is intended to measure. The COI may be
identical to the selected meaningful aspect of feeling or
function. Frequently, however, the COI is a simpliﬁed form
or component of a feeling or function that is not an inherently
meaningful feeling or function of a patient’s typical life, that
is, not a complete meaningful health aspect, but thought to be
indirectly well related to a meaningful health aspect.
Context of Use (COU): A description of the speciﬁcs of the study
design, how the COA is used within the study, and result
interpretation.
Directly Meaningful COA: A COA that directly measures the
patient’s actual feelings or a function(s). The feelings or
function(s) must be meaningful to the patient and part of
the patient’s typical (normal) life. All COAs are intended to
measure the COI. COAs are directly meaningful only when the
COI is the same as the intended meaningful health aspect.Feeling, Functioning, Survival: Aspects of a person’s usual
(typical) life that may be adversely altered by a disease.
Indirectly Meaningful COA: A COA that indirectly evaluates
feelings or functions that are meaningful and are part of the
patient’s typical life. Indirectly meaningful COAs are, how-
ever, intended to have a good relationship with the mean-
ingful health aspect.
Meaningful Health Aspect: An aspect of health (feelings,
functions, or survival) affected by the disease that the patient
cares about and has a preference that it 1) does not become
worse, 2) improves, or 3) is prevented.
Observer Reported Outcome (ObsRO): A COA in which
observations can be made, appraised, and recorded by a
person other than the patient who does not require speci-
alized professional training. The rating is nonetheless inﬂu-
enced by the perspective of the observer.
Outcome Assessment: A measuring instrument that provides
a rating or score (categorical or continuous) that is intended
to represent some aspect of the patient’s medical status.
Appropriate outcome assessments may include both COAs
and biomarkers.
Patient Reported Outcome (PRO): A COA in which the report
comes directly from the patient. The patients’ responses to
questions about their health condition are recorded without
amendment or interpretation by anyone else.
Performance Outcome (PerfO): A COA in which the patient
is assessed by performing a deﬁned task that is quantiﬁed in
a speciﬁed way. Although a member of the investigator team
may administer the PerfO task and monitor the patient’s
performance, the investigator does not apply judgment to
quantify the performance.
Study Endpoint: The outcome result obtained in a clinical trial
and interpreted to determine whether the therapy has pro-
vided a treatment beneﬁt. Study endpoints are composed of a
speciﬁc outcome assessment, measured at speciﬁed times
during the study, and analyzed according to a speciﬁed
statistical method.
Treatment Beneﬁt: A favorable effect on a meaningful aspect of
how patients feel or function in their life, or on survival. It is
an effect on an aspect of health affected by the disease that is
an alteration in feeling or functioning, about which the
patient cares that it is affected, and has a preference that it
does not become worse, improves, or is prevented. The aspect
of feeling or functions affected by the therapy should be what
occurs in the patient’s usual (typical) life.Acknowledgement
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